Change in plasma Aβ peptides and onset of dementia in adults with Down syndrome

Neurology

Volumn 75, Issue 18, 2010, Pages 1639-1644

  Schupf, N ^a,b,c   Zigman, W B ^c   Tang, M X ^a,b   Pang, D ^b   Mayeux, R ^a,b   Mehta, P ^c   Silverman, W ^d,e  

^a Department of Epidemiology   (United States)

^b New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^c NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

^d KENNEDY KRIEGER INSTITUTE   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

ADULT; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CLINICAL ASSESSMENT; COGNITION; CONTROLLED STUDY; DOWN SYNDROME; FEMALE; FOLLOW UP; GENOTYPE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; BLOOD; COHORT ANALYSIS; GENETICS; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; TIME;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEINS E; COHORT STUDIES; DOWN SYNDROME; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PSYCHIATRIC STATUS RATING SCALES; TIME FACTORS;

EID: 78349266860     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181fb448b     Document Type: Article

References (38)

1. Selkoe DJ. Normal and abnormal biology of the beta-amyloid precursor protein. Annu Rev Neurosci 1994;17: 489-517.
2. Naslund J, Haroutonian V, Mohs R, et al. Correlation between elevated levels ofamyloid B-peptide in the brain and cognitive decline. JAMA 2000;283:1571-1577.
3. Blennow K, Vanmechelen E. CSF markers for pathogenic processes in Alzheimer's disease: diagnostic implications and use in clinical neurochemistry. Brain Res Bull 2003; 61:235-242.
4. Hansson O, Zetterberg H, Buchhave P, et al. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement Geri-atrCogn Disord2007;23:316-320.
5. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction ofcognitive decline in nondemented older adults. Arch Neurol 2007;64:343-349.
6. Mayeux R, Tang MX, Jacobs DM, et al. Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease. Ann Neurol 1999;46:412-416.
7. Mayeux R, Honig LS, Tang MX, et al. Plasma A [beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology 2003;61:1185-1190.
8. van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM. Plasma A beta(1-40) and Abeta(1-42) and the risk of dementia: aprospective case-cohort study. Lan-cet Neurol 2006;5:655-660.
9. Assini A, Cammarata S, Vitali A, et al. Plasma levels of amyloid beta-protein 42 are increased in women with mild cognitive impairment. Neurology 2004;63:828-831.
10. Pomara N, Willoughby LM, Sidtis JJ, Mehta PD. Selective reductions in plasma Abeta 1-42 in healthy elderly sub-jects during longitudinal follow-up: a preliminary report. Am J Geriatr Psychiatry 2005;13:914-917.
11. Schupf N, Patel B, Pang D, et al. Elevated plasma beta-amyloid peptide Abeta(42) levels, incident dementia, and mortality in Down syndrome. Arch Neurol 2007;64:1007-1013.
12. Schupf N, Tang MX, Fukuyama H, et al. Peripheral Abeta subspecies as risk biomarkers ofAlzheimer's disease. Proc Natl Acad Sci USA 2008;105:14052-14057.
13. Sobow T, Flirski M, Kloszewska I, Liberski PP. Plasma levels of alpha beta peptides are altered in amnestic mild cognitive impairment but not in sporadic Alzheimer's dis-ease. Acta Neurobiol Exp 2005;65:117-124.
14. Okereke OI, Xia W, Selkoe DJ, Grodstein F. Ten-year change in plasma amyloid beta levels and late-life cognitive decline. Arch Neurol 2009;66:1247-1253.
15. Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Grow-don JH, Irizarry MC. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neu-rol 2003;60:958-964.
16. Hansson O, Zetterberg H, Vanmechelen E, et al. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conver-sion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging 2010;31:357-367.
17. Graff-Radford NR, Crook JE, Lucas J, et al. Association of low plasma Abeta42/Abeta40 ratios with increased immi-nent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 2007;64:354-362.
18. Lambert JC, Schraen-Maschke S, Richard F, etal.Association of plasma amyloid betawith risk of dementia: the prospective Three-City Study. Neurology 2009;73:847-853.
19. Sundelof J, Giedraitis V, Irizarry MC, et al. Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study. Arch Neurol 2008;65:256-263.
20. Jack CR Jr, Lowe VJ, Weigand SD, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzhei-mer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009;132:1355-1365.
21. Matsubara E, Ghiso J, Frangione B, et al. Lipoprotein-free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer's disease and Down's syndrome. Ann Neurol 1999;45:537-541.
22. Mehta PD, Dalton AJ, Mehta SP, Kim KS, Sersen EA, Wisniewski HM. Increased plasma amyloid beta protein 1-42 levels in Down syndrome. Neurosci Lett 1998;241: 13-16.
23. Schupf N, Patel B, Silverman W, et al. Elevated plasma amyloid beta-peptide 1-42 and onset of dementia in adults with Down syndrome. Neurosci Lett 2001;301: 199-203.
24. Tokuda T, Fukushima T, Ikeda S, et al. Plasma levels ofamy-loid beta proteins Abeta1-40 and Abeta1-42(43) are ele-vated in Down's syndrome. Ann Neurol 1997;41:271-273.
25. Zigman WB, Schupf N, Sersen E, Silverman W. Preva-lence of dementia in adults with and without Down syn-drome. Am J Ment Retard 1996;100:403-412.
26. Rumble B, Retallack R, Hilbich C, et al. Amyloid A4 pro-tein and its precursor in Down's syndrome and Alzhei-mer's disease. N Engl J Med 1989;320:1446-1452.
27. Silverman W, Schupf N, Zigman W, et al. Dementia in adults with mental retardation: assessment at a single point in time. Am J Ment Retard 2004;109:111-125.
28. Aylward EH, Burt DB, Thorpe LU, Lai F, Dalton A. Di-agnosis of dementia in individuals with intellectual disabil-ity. J Intellect Disabil Res 1997;41:152-164.
29. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545-548.
30. Ringman JM, Younkin SG, Pratico D, et al. Biochemical markers in persons with preclinical familial Alzheimer dis-ease. Neurology 2008;71:85-92.
31. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid beta-protein similar to that in the senile plaques ofAlzhei-mer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease [see comments]. Nat Med 1996;2:864-870.
32. Ertekin-Taner N, Younkin LH, Yager DM, et al. Plasma amyloid beta protein is elevated in late-onset Alzheimer disease families. Neurology 2008;70:596-606.
33. Locascio JJ, Fukumoto H, Yap L, et al. Plasma amyloid beta-protein and C-reactive protein in relation to the rate of progression of Alzheimer disease. Arch Neurol 2008;65: 776-785.
34. Stomrud E, Hansson O, Zetterberg H, Blennow K, Mint-hon L, Londos E. Correlation of longitudinal cerebrospi-nal fluid biomarkers with cognitive decline in healthy older adults. Arch Neurol 2010;67:217-223.
35. Mehta PD, Pirttila T, Patrick BA, Barshatzky M, Mehta SP. Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neurosci Lett 2001;304:102-106.
36. Le Bastard N, Aerts L, Leurs J, Blomme W, De Deyn P, Engelborghs S. No correlation between time-linked plasma and CSF Abeta levels. Neurochem Int 2009;55: 820-825.
37. Matsubara E, Hirai S, Amari M, et al. Alpha 1-antichymotrypsin as a possible biochemical marker for Alzheimer-type dementia. Ann Neurol 1990;28:561-567.
38. Chen M, Inestrosa NC, Ross GS, Fernandez HL. Plate-lets are the primary source of amyloid beta-peptide in human blood. Biochem Biophys Res Commun 1995; 213:96-103